首页 > 最新文献

Ophthalmologica最新文献

英文 中文
Comparison of Chandelier-Assisted versus Standard Scleral Buckling for the Treatment of Primary Rhegmatogenous Retinal Detachment: A Systematic Review and Meta-Analysis. 治疗原发性风湿性视网膜脱离的吊灯辅助巩膜扣带术与标准巩膜扣带术的比较:系统回顾与元分析》。
IF 2.1 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-01-01 Epub Date: 2024-08-19 DOI: 10.1159/000540820
Yung-Shuo Kao, Chia-Yun Chen, Yu-Te Huang, San-Ni Chen

Introduction: Compare the anatomical and functional outcomes, operation duration, and complication rates between standard scleral buckling (SSB) and chandelier-assisted scleral buckling (CSB) for phakic eyes with rhegmatogenous retinal detachment (RRD).

Methods: PubMed, Embase, and Cochrane Library databases were searched from inception to June 2024. The primary endpoint will be set as a final success. The secondary endpoint will be primary success, operation time, and final BCVA.

Results: Our meta-analysis showed that there is no statistical difference between CSB and SSB for the final success rate (RR = 1.00, 95% CI = 0.97-1.03). For the primary success rate, there is no statistical difference between CSB and SSB (RR = 1.00, 95% CI = 0.94-1.06). For operation time, our meta-analysis showed that the CSB group is less than the SSB group (pooled MD = -15.8, 95% CI = -22.60 to -9.00). For postoperative complications, our study shows that the CSB group presented with lower pooled risk than the SSB group (RR = 0.59, 95% CI = 0.41-0.89). There is a trend that the ERM formation risk is higher in the CSB group if there is no routine suture for the sclerotomy (p = 0.08).

Conclusion: CSB showcases a significantly reduced operation duration and less postoperative complication in contrast to the SSB group, maintaining comparable primary and ultimate anatomical success rates as well as final BCVA.

简介:比较标准巩膜扣带术(SSB)和吊灯辅助巩膜扣带术(CSB)治疗流变性视网膜脱离(RRD)的解剖和功能结果、手术时间和并发症发生率。方法 检索从开始到 2024 年 6 月的 PubMed、Embase 和 Cochrane Library 数据库。主要终点将设定为最终成功。次要终点为主要成功率、手术时间和最终 BCVA。结果 我们的荟萃分析表明,CSB 和 SSB 在最终成功率上没有统计学差异(RR=1.00,95%CI=0.97-1.03)。在初次成功率方面,CSB 和 SSB 没有统计学差异(RR=1.00,95%CI=0.94-1.06)。在手术时间方面,我们的荟萃分析显示 CSB 组少于 SSB 组(汇总 MD= -15.8,95%CI=-22.60- -9.00)。对于术后并发症,我们的研究显示,CSB 组的集合风险低于 SSB 组(RR=0.59,95%CI=0.41-0.89)。有一种趋势表明,如果硬膜切开术没有常规缝合,CSB 组 ERM 形成的风险更高(P=0.08)。结论 与 SSB 组相比,CSB 明显缩短了手术时间,减少了术后并发症,保持了相当的初次和最终解剖成功率以及最终 BCVA。
{"title":"Comparison of Chandelier-Assisted versus Standard Scleral Buckling for the Treatment of Primary Rhegmatogenous Retinal Detachment: A Systematic Review and Meta-Analysis.","authors":"Yung-Shuo Kao, Chia-Yun Chen, Yu-Te Huang, San-Ni Chen","doi":"10.1159/000540820","DOIUrl":"10.1159/000540820","url":null,"abstract":"<p><strong>Introduction: </strong>Compare the anatomical and functional outcomes, operation duration, and complication rates between standard scleral buckling (SSB) and chandelier-assisted scleral buckling (CSB) for phakic eyes with rhegmatogenous retinal detachment (RRD).</p><p><strong>Methods: </strong>PubMed, Embase, and Cochrane Library databases were searched from inception to June 2024. The primary endpoint will be set as a final success. The secondary endpoint will be primary success, operation time, and final BCVA.</p><p><strong>Results: </strong>Our meta-analysis showed that there is no statistical difference between CSB and SSB for the final success rate (RR = 1.00, 95% CI = 0.97-1.03). For the primary success rate, there is no statistical difference between CSB and SSB (RR = 1.00, 95% CI = 0.94-1.06). For operation time, our meta-analysis showed that the CSB group is less than the SSB group (pooled MD = -15.8, 95% CI = -22.60 to -9.00). For postoperative complications, our study shows that the CSB group presented with lower pooled risk than the SSB group (RR = 0.59, 95% CI = 0.41-0.89). There is a trend that the ERM formation risk is higher in the CSB group if there is no routine suture for the sclerotomy (p = 0.08).</p><p><strong>Conclusion: </strong>CSB showcases a significantly reduced operation duration and less postoperative complication in contrast to the SSB group, maintaining comparable primary and ultimate anatomical success rates as well as final BCVA.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"345-354"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11614423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142004938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Landscape of Central Serous Chorioretinopathy in Germany: Retina.net CSC Registry Report Number 1. 德国中心性浆液性脉络膜视网膜病变的临床概况 - Retina.net CSC 注册中心第 1 号报告。
IF 2.1 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-01-01 Epub Date: 2024-02-16 DOI: 10.1159/000535930
Clemens A Lange, Charlotte Ohlmeier, Anna Kiskämper, Christoph von Schwarzkopf, Hinrich Hufnagel, Markus Gruber, Benedikt Schworm, Ulrike Brocks, Franziska Reinking, Lisa Schreiner, Yoko Miura, Milena Grundel, Tibor Lohmann, Christoph R Clemens, Maria-Andreea Gamulescu, Nicole Eter, Salvatore Grisanti, Siegfried Priglinger, Martin S Spitzer, Peter Walter, Hansjürgen A Agostini, Andreas Stahl, Laurenz J B Pauleikhoff

Introduction: The German Registry of central serous chorioretinopathy (CSC) collects data on CSC patients in a nationwide multicenter approach to analyze epidemiology, risk factors, clinical presentations, as well as diagnosis and treatment patterns.

Methods: In this multicenter cohort study, patients with CSC were enrolled in nine tertiary referral centers in Germany between January 2022 and June 2023. After consenting to the study, demographic data, risk factors, reported symptoms, best-corrected visual acuity (BCVA), funduscopic findings, disease severity, and diagnostic and treatment decisions were recorded and analyzed.

Results: A total of 539 eyes of 411 CSC patients were enrolled in this study including 308 males (75%) and 103 females (25%). Patients were predominantly of Caucasian origin and had a mean age of 55.5 years (IQR 41.0-70.0). 28% of eyes were classified as acute (<4 months duration) CSC, 28% as chronic (>4 months duration) CSC, 21% as inactive CSC, 11% as chronic atrophic CSC, and 12% as CSC with secondary CNV. 128 patients (31%) demonstrated bilateral CSC. The most common risk factors reported were psychological stress (52%), smoking (38%), arterial hypertension (38%), and a history of or current use of steroids (30%). Most frequently encountered symptoms included decreased visual acuity (76%), metamorphopsia (49%), relative scotoma (47%), blurred vision (19%), and dyschromatopsia (9%). The mean logMAR BCVA on initial examination was 0.2 (≈20/30, IQR 0.2-0.4) but showed significant variation with a tendency of lower BCVA in chronic cases. At the baseline visit, 74% of the overall cohort received no treatment, while 19% underwent local treatment and only 2% underwent systemic treatment. Of the local therapies, anti-VEGF injections were the most frequently performed procedure (33%, mainly for secondary CNV), followed by micropulse laser (28%), focal nonpulsed laser (23%), verteporfin photodynamic therapy (14%), and nonsteroidal anti-inflammatory eye drops (2%). Among intravitreal anti-VEGF agents, aflibercept was used most frequently, followed by bevacizumab and ranibizumab.

Conclusion: This registry represents one of the largest cohorts of European patients with CSC to date. Patient age and the proportion of women were higher than expected and bilateral active disease was lower than anticipated, highlighting that neither age nor gender should be overemphasized when diagnosing CSC. Therapeutic interventions are heterogeneous and include verteporfin photodynamic therapy, micropulse laser, and anti-VEGF injections in case of secondary CNV.

背景:德国中央浆液性脉络膜视网膜病变(CSC)登记处通过全国多中心方法收集CSC患者的数据,以分析流行病学、风险因素、临床表现以及诊断和治疗模式:在这项多中心队列研究中,德国九家三级转诊中心在 2022 年 1 月至 2023 年 6 月期间招募了 CSC 患者。在同意参与研究后,记录并分析了人口统计学数据、风险因素、报告症状、最佳矫正视力(BCVA)、眼底检查结果、疾病严重程度以及诊断和治疗决定:本研究共纳入了 411 名 CSC 患者的 539 只眼睛,其中男性 308 只(占 75%),女性 103 只(占 25%)。患者主要为白种人,平均年龄为 55.5 岁(IQR 41.0 - 70.0)。28%的眼睛被归类为急性(病程4个月)CSC,21%为非活动性CSC,11%为慢性萎缩性CSC,12%为伴有继发性CNV的CSC。128名患者(31%)表现为双侧CSC。据报告,最常见的风险因素是心理压力(52%)、吸烟(38%)、动脉高血压(38%)以及曾使用或正在使用类固醇(30%)。最常见的症状包括视力下降(76%)、变色(49%)、相对视网膜朦胧(47%)、视力模糊(19%)和色觉障碍(9%)。初次检查时,BCVA 的平均对数为 0.2(≈20/30,IQR 0.2 - 0.4),但慢性病例的 BCVA 有明显下降趋势。在基线检查中,74%的患者没有接受任何治疗,19%的患者接受了局部治疗,只有2%的患者接受了全身治疗。在局部治疗中,抗血管内皮生长因子注射是最常见的治疗方法(33%,主要用于继发性 CNV),其次是微脉冲激光(28%)、局灶非脉冲激光(23%)、光动力疗法(14%)和非甾体抗炎眼药水(2%)。在玻璃体内抗血管内皮生长因子药物中,阿弗利百普最常用,其次是贝伐珠单抗和雷尼珠单抗:该登记代表了迄今为止欧洲最大的CSC患者队列之一。患者年龄和女性比例高于预期,双侧活动性疾病低于预期,这表明在诊断CSC时不应过分强调年龄或性别。治疗干预措施多种多样,包括光动力疗法、微脉冲激光和继发性 CNV 的抗血管内皮生长因子注射。
{"title":"Clinical Landscape of Central Serous Chorioretinopathy in Germany: Retina.net CSC Registry Report Number 1.","authors":"Clemens A Lange, Charlotte Ohlmeier, Anna Kiskämper, Christoph von Schwarzkopf, Hinrich Hufnagel, Markus Gruber, Benedikt Schworm, Ulrike Brocks, Franziska Reinking, Lisa Schreiner, Yoko Miura, Milena Grundel, Tibor Lohmann, Christoph R Clemens, Maria-Andreea Gamulescu, Nicole Eter, Salvatore Grisanti, Siegfried Priglinger, Martin S Spitzer, Peter Walter, Hansjürgen A Agostini, Andreas Stahl, Laurenz J B Pauleikhoff","doi":"10.1159/000535930","DOIUrl":"10.1159/000535930","url":null,"abstract":"<p><strong>Introduction: </strong>The German Registry of central serous chorioretinopathy (CSC) collects data on CSC patients in a nationwide multicenter approach to analyze epidemiology, risk factors, clinical presentations, as well as diagnosis and treatment patterns.</p><p><strong>Methods: </strong>In this multicenter cohort study, patients with CSC were enrolled in nine tertiary referral centers in Germany between January 2022 and June 2023. After consenting to the study, demographic data, risk factors, reported symptoms, best-corrected visual acuity (BCVA), funduscopic findings, disease severity, and diagnostic and treatment decisions were recorded and analyzed.</p><p><strong>Results: </strong>A total of 539 eyes of 411 CSC patients were enrolled in this study including 308 males (75%) and 103 females (25%). Patients were predominantly of Caucasian origin and had a mean age of 55.5 years (IQR 41.0-70.0). 28% of eyes were classified as acute (&lt;4 months duration) CSC, 28% as chronic (&gt;4 months duration) CSC, 21% as inactive CSC, 11% as chronic atrophic CSC, and 12% as CSC with secondary CNV. 128 patients (31%) demonstrated bilateral CSC. The most common risk factors reported were psychological stress (52%), smoking (38%), arterial hypertension (38%), and a history of or current use of steroids (30%). Most frequently encountered symptoms included decreased visual acuity (76%), metamorphopsia (49%), relative scotoma (47%), blurred vision (19%), and dyschromatopsia (9%). The mean logMAR BCVA on initial examination was 0.2 (≈20/30, IQR 0.2-0.4) but showed significant variation with a tendency of lower BCVA in chronic cases. At the baseline visit, 74% of the overall cohort received no treatment, while 19% underwent local treatment and only 2% underwent systemic treatment. Of the local therapies, anti-VEGF injections were the most frequently performed procedure (33%, mainly for secondary CNV), followed by micropulse laser (28%), focal nonpulsed laser (23%), verteporfin photodynamic therapy (14%), and nonsteroidal anti-inflammatory eye drops (2%). Among intravitreal anti-VEGF agents, aflibercept was used most frequently, followed by bevacizumab and ranibizumab.</p><p><strong>Conclusion: </strong>This registry represents one of the largest cohorts of European patients with CSC to date. Patient age and the proportion of women were higher than expected and bilateral active disease was lower than anticipated, highlighting that neither age nor gender should be overemphasized when diagnosing CSC. Therapeutic interventions are heterogeneous and include verteporfin photodynamic therapy, micropulse laser, and anti-VEGF injections in case of secondary CNV.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"95-106"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139900298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blue Dye-Assisted Intraoperative Optical Coherence Tomography for Macular Surgery. 用于黄斑手术的蓝染料辅助术中光学相干断层扫描。
IF 2.1 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-01-01 Epub Date: 2024-08-27 DOI: 10.1159/000541056
Marco Pellegrini, Ginevra Adamo, Laura Sarti, Pietro Maria Talli, Francesco Nasini, Marco Mura

Introduction: The purpose of this study was to evaluate whether vital blue dyes could enhance the contrast of intraoperative optical coherence tomography (OCT) during macular surgery.

Methods: Consecutive patients undergoing elective pars plana vitrectomy for vitreomacular interface disorders were enrolled. Intraoperative OCT was performed with the Artevo 800 microscope (Carl Zeiss Meditec AG, Jena, Germany) before and after injection of 0.2 mL of Trypan Blue and Brilliant Blue G Ophthalmic Solution. The OCT contrast ratio was measured with ImageJ, while the overall scan quality was subjectively classified using a 4-point scale.

Results: Ten eyes of 10 patients were enrolled in the study. The OCT contrast ratio was 9.39 ± 5.35 without blue dye and significantly improved to 14.31 ± 10.50 after blue dye injection (p = 0.027). The percentage of patients with a grade 4 scan quality also significantly improved (from 40% without blue dye to 90% with blue dye injection; p = 0.012).

Conclusion: The use of blue dyes during intraoperative OCT is an effective strategy for improving contrast and scan quality without affecting the surgical time and workflow.

简介本研究旨在评估生命蓝染料能否增强黄斑手术中术中 OCT 的对比度:方法:连续招募因玻璃体黄斑界面紊乱而接受选择性玻璃体旁切除术的患者。在注射 0.2 mL 胰酶蓝和亮蓝 G 眼科溶液之前和之后,使用 Artevo 800 显微镜(卡尔蔡司 Meditec AG,德国耶拿,Jena)进行术中 OCT 扫描。OCT 对比度用 ImageJ 进行测量,整体扫描质量用 4 分制进行主观评分:结果:10 名患者的 10 只眼睛参加了研究。未注射蓝色染料时,OCT 对比度为 9.39 ± 5.35,注射蓝色染料后,对比度显著提高至 14.31 ± 10.50(P = 0.027)。扫描质量为 4 级的患者比例也明显提高(从未用到蓝色染料时的 40% 提高到注射蓝色染料后的 90%;P = 0.012):结论:术中 OCT 使用蓝色染料是提高对比度和扫描质量的有效策略,且不会影响手术时间和工作流程。
{"title":"Blue Dye-Assisted Intraoperative Optical Coherence Tomography for Macular Surgery.","authors":"Marco Pellegrini, Ginevra Adamo, Laura Sarti, Pietro Maria Talli, Francesco Nasini, Marco Mura","doi":"10.1159/000541056","DOIUrl":"10.1159/000541056","url":null,"abstract":"<p><strong>Introduction: </strong>The purpose of this study was to evaluate whether vital blue dyes could enhance the contrast of intraoperative optical coherence tomography (OCT) during macular surgery.</p><p><strong>Methods: </strong>Consecutive patients undergoing elective pars plana vitrectomy for vitreomacular interface disorders were enrolled. Intraoperative OCT was performed with the Artevo 800 microscope (Carl Zeiss Meditec AG, Jena, Germany) before and after injection of 0.2 mL of Trypan Blue and Brilliant Blue G Ophthalmic Solution. The OCT contrast ratio was measured with ImageJ, while the overall scan quality was subjectively classified using a 4-point scale.</p><p><strong>Results: </strong>Ten eyes of 10 patients were enrolled in the study. The OCT contrast ratio was 9.39 ± 5.35 without blue dye and significantly improved to 14.31 ± 10.50 after blue dye injection (p = 0.027). The percentage of patients with a grade 4 scan quality also significantly improved (from 40% without blue dye to 90% with blue dye injection; p = 0.012).</p><p><strong>Conclusion: </strong>The use of blue dyes during intraoperative OCT is an effective strategy for improving contrast and scan quality without affecting the surgical time and workflow.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"341-344"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142081204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pars Plana Vitrectomy with or without Internal Limiting Membrane Peel for Epiretinal Membrane: A Systematic Review and Meta-Analysis. 带或不带内界膜剥离的视网膜前膜平坦部玻璃体切割术:一项系统综述和荟萃分析。
IF 2.1 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-01-01 Epub Date: 2023-10-28 DOI: 10.1159/000534851
Andrew Mihalache, Ryan S Huang, Haleema Ahmed, Nikhil S Patil, Marko M Popovic, Peter J Kertes, Rajeev H Muni

Background: The safety and effectiveness of pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling remains poorly understood for the treatment of epiretinal membrane (ERM).

Objectives: Our study aims to compare the safety and effectiveness of PPV with and without ILM peeling for ERM.

Methods: A systematic literature search was conducted on Ovid MEDLINE, Embase, Cochrane Library, and Google Scholar from January 2000 to January 2023 for comparative studies reporting visual and anatomical outcomes for patients with ERM that received PPV with or without ILM peeling. Primary outcomes included best-corrected visual acuity (BCVA) at last study observation and change in BCVA from baseline. Secondary outcomes included retinal thickness (RT) at last study observation, change in RT from baseline, risk of ERM recurrence, and adverse events. A random-effects meta-analysis was performed. Risk of bias of randomized controlled trials was assessed using the Risk of Bias 2 tool of observational studies using the Risk of Bias in Non-randomized Studies of Interventions-I tool. The certainty of evidence of outcomes was evaluated using Grading of Recommendations, Assessment, Development and Evaluation criteria.

Results: Nineteen studies reporting on 1,291 eyes at baseline were included. PPV with and without ILM peel achieved a similar BCVA at last study observation (p = 0.68) and change in BCVA from baseline (p = 0.79). These findings remained consistent irrespective of whether simultaneous phacoemulsification was performed. PPV with ILM peel achieved a significantly lower incidence of ERM recurrence (risk ratio [RR] = 0.26, 95% CI = [0.13, 0.51], p < 0.0001) and additional surgery (RR = 0.17, 95% CI = [0.04, 0.74], p = 0.02) compared to PPV without ILM peel.

Conclusion: PPV with and without ILM peel achieved a similar BCVA at last study observation in ERM patients. Patients treated with PPV and ILM peel also had a reduced risk of ERM recurrence and lower reoperation risk. These conclusions are associated with a moderate certainty of evidence and potential for bias from multiple non-randomized studies.

背景:带内界膜(ILM)剥离的平坦部玻璃体切除术(PPV)治疗视网膜前膜(ERM)的安全性和有效性尚不清楚。目的:我们的研究旨在比较PPV在有和没有ILM剥离的情况下用于ERM的安全性和有效性。方法:从2000年1月到2023年1月,在Ovid MEDLINE、Embase、Cochrane Library和Google Scholar上进行了系统的文献检索,以比较研究报告接受PPV伴或不伴ILM剥离的ERM患者的视觉和解剖结果。主要结果包括上次研究观察时的最佳矫正视力(BCVA)和BCVA与基线的变化。次要结果包括上次研究观察的视网膜厚度(RT)、RT与基线的变化、ERM复发的风险和不良事件。进行随机效应荟萃分析。随机对照试验(RCTs)的偏倚风险使用ROBINS-I工具进行观察性研究的ROB2工具进行评估。使用GRADE标准评估结果证据的确定性。结果:纳入19项研究,报告基线时1291只眼睛。在最后一次研究观察中,有和没有ILM剥离的PPV获得了相似的BCVA(p=0.68)和BCVA与基线的变化(p=0.79)。无论是否同时进行超声乳化,这些发现都保持一致。PPV和ILM剥离显著降低了ERM复发的发生率(RR=0.26,95%CI=[0.13,0.51]结论:在ERM患者的最后一次研究观察中,有和没有ILM剥离的PPV获得了相似的BCVA。接受PPV和ILM剥离治疗的患者也降低了ERM复发的风险,并降低了再次手术的风险。这些结论与多个非随机研究的证据的适度确定性和潜在的偏倚有关。
{"title":"Pars Plana Vitrectomy with or without Internal Limiting Membrane Peel for Epiretinal Membrane: A Systematic Review and Meta-Analysis.","authors":"Andrew Mihalache, Ryan S Huang, Haleema Ahmed, Nikhil S Patil, Marko M Popovic, Peter J Kertes, Rajeev H Muni","doi":"10.1159/000534851","DOIUrl":"10.1159/000534851","url":null,"abstract":"<p><strong>Background: </strong>The safety and effectiveness of pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling remains poorly understood for the treatment of epiretinal membrane (ERM).</p><p><strong>Objectives: </strong>Our study aims to compare the safety and effectiveness of PPV with and without ILM peeling for ERM.</p><p><strong>Methods: </strong>A systematic literature search was conducted on Ovid MEDLINE, Embase, Cochrane Library, and Google Scholar from January 2000 to January 2023 for comparative studies reporting visual and anatomical outcomes for patients with ERM that received PPV with or without ILM peeling. Primary outcomes included best-corrected visual acuity (BCVA) at last study observation and change in BCVA from baseline. Secondary outcomes included retinal thickness (RT) at last study observation, change in RT from baseline, risk of ERM recurrence, and adverse events. A random-effects meta-analysis was performed. Risk of bias of randomized controlled trials was assessed using the Risk of Bias 2 tool of observational studies using the Risk of Bias in Non-randomized Studies of Interventions-I tool. The certainty of evidence of outcomes was evaluated using Grading of Recommendations, Assessment, Development and Evaluation criteria.</p><p><strong>Results: </strong>Nineteen studies reporting on 1,291 eyes at baseline were included. PPV with and without ILM peel achieved a similar BCVA at last study observation (p = 0.68) and change in BCVA from baseline (p = 0.79). These findings remained consistent irrespective of whether simultaneous phacoemulsification was performed. PPV with ILM peel achieved a significantly lower incidence of ERM recurrence (risk ratio [RR] = 0.26, 95% CI = [0.13, 0.51], p &lt; 0.0001) and additional surgery (RR = 0.17, 95% CI = [0.04, 0.74], p = 0.02) compared to PPV without ILM peel.</p><p><strong>Conclusion: </strong>PPV with and without ILM peel achieved a similar BCVA at last study observation in ERM patients. Patients treated with PPV and ILM peel also had a reduced risk of ERM recurrence and lower reoperation risk. These conclusions are associated with a moderate certainty of evidence and potential for bias from multiple non-randomized studies.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"30-43"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71413289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Twelve-Month Outcomes of Three Episcleral Surgeries in Treatment of Rhegmatogenous Retinal Detachment. 治疗风湿性视网膜脱离的三种巩膜外手术的十二个月疗效。
IF 2.1 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-01-01 Epub Date: 2024-06-18 DOI: 10.1159/000539854
Zigan Zhou, Binghua Guo, Hantao Zhou, Chen Yang, Jinghao Mei, Chuying Deng, Ronghan Wu, Zhong Lin

Introduction: The aim of this study was to compare the long-term outcomes of conventional scleral buckling (CSB), modified scleral buckling (MSB), and scleral encircling (SE) in the treatment of rhegmatogenous retinal detachment and identify factors influencing the outcomes.

Methods: This comparative, retrospective cohort study assigned patients to CSB, MSB, and SE groups. The follow-up was 12 months, and the reattachment rate, complication rate, visual acuity, number of newly discovered tears during surgery, and changes in diopters were compared among the three surgeries. Influential factors on anatomical and functional reattachment were identified.

Results: There were no significant differences in the primary reattachment rate, overall complication rate, or best corrected visual acuity at 6 or 12 months among the three groups. The MSB group had a higher number of newly discovered tears during surgery compared with the other two groups. At 12 months of post-surgery, the SE group displayed the greatest change of diopter, whereas the MSB group showed the least change. The surgical approach did not influence the primary reattachment rate. Long-term visual outcomes were influenced by factors including sex, preoperative visual acuity, macular status, and duration of symptoms.

Conclusion: MSB is an effective method for treating rhegmatogenous retinal detachment. Its advantages include the ability to identify smaller tears and induce minimal changes in diopter.

简介比较传统巩膜扣带术(CSB)、改良巩膜扣带术(MSB)和巩膜环绕术(SE)治疗流变性视网膜脱离的长期疗效,并确定影响疗效的因素:这项比较性、回顾性队列研究将患者分为 CSB 组、MSB 组和 SE 组。随访时间为 12 个月,比较了三种手术的再粘连率、并发症发生率、视力、手术中新发现的裂孔数量以及斜度变化。结果发现了影响解剖和功能性再接合的因素:结果:三组患者的初次再接合率、总体并发症发生率、6 个月或 12 个月后的最佳矫正视力均无明显差异。与其他两组相比,MSB 组在手术中新发现的裂孔数量较多。术后 12 个月时,SE 组的屈光度变化最大,而 MSB 组的变化最小。手术方法并不影响初次再接合率。长期视力结果受性别、术前视力、黄斑状态和症状持续时间等因素的影响:结论:MSB 是治疗流变性视网膜脱离的有效方法。结论:MSB 是一种治疗流变性视网膜脱离的有效方法,其优点是能识别较小的裂孔,并将屈光度的变化降至最低。
{"title":"Twelve-Month Outcomes of Three Episcleral Surgeries in Treatment of Rhegmatogenous Retinal Detachment.","authors":"Zigan Zhou, Binghua Guo, Hantao Zhou, Chen Yang, Jinghao Mei, Chuying Deng, Ronghan Wu, Zhong Lin","doi":"10.1159/000539854","DOIUrl":"10.1159/000539854","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to compare the long-term outcomes of conventional scleral buckling (CSB), modified scleral buckling (MSB), and scleral encircling (SE) in the treatment of rhegmatogenous retinal detachment and identify factors influencing the outcomes.</p><p><strong>Methods: </strong>This comparative, retrospective cohort study assigned patients to CSB, MSB, and SE groups. The follow-up was 12 months, and the reattachment rate, complication rate, visual acuity, number of newly discovered tears during surgery, and changes in diopters were compared among the three surgeries. Influential factors on anatomical and functional reattachment were identified.</p><p><strong>Results: </strong>There were no significant differences in the primary reattachment rate, overall complication rate, or best corrected visual acuity at 6 or 12 months among the three groups. The MSB group had a higher number of newly discovered tears during surgery compared with the other two groups. At 12 months of post-surgery, the SE group displayed the greatest change of diopter, whereas the MSB group showed the least change. The surgical approach did not influence the primary reattachment rate. Long-term visual outcomes were influenced by factors including sex, preoperative visual acuity, macular status, and duration of symptoms.</p><p><strong>Conclusion: </strong>MSB is an effective method for treating rhegmatogenous retinal detachment. Its advantages include the ability to identify smaller tears and induce minimal changes in diopter.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"214-223"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141420286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Outcomes of a New Monofocal Intraocular Lens in Patients Undergoing Phacovitrectomy for Idiopathic Epiretinal Membrane. 在因特发性视网膜外膜而接受虹膜切除术的患者中使用新型单焦点眼内透镜的临床效果。
IF 2.1 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-01-01 Epub Date: 2024-07-30 DOI: 10.1159/000540362
Tomislav Jukić, Gentian Bajraktari, Nenad Vukojević, Martin Oroz, Andrea Radolović, Krešimir Mandić, Miro Kalauz

Introduction: The purpose of this study was to evaluate the clinical outcomes and quality of life of newly generated monofocal intraocular lens (IOL) in patients diagnosed with idiopathic epiretinal membrane (IEM) following phacovitrectomy.

Methods: In this prospective study, 42 patients with IEM and cataract underwent pars plana vitrectomy. They were divided into the ICB00 group (21 patients) and the ZCB00 group (21 patients). Data collected before and after the surgery were compared between the two groups, including uncorrected distance visual acuity (UDVA), uncorrected intermediate visual acuity (UIVA), vision-related quality of life (VRQOL), intraocular pressure, contrast sensitivity (CS), and central macular thickness (CMT).

Results: The preoperative characteristics of the two groups showed no significant differences. However, at the 6-month follow-up after surgery, there were significant improvements in UDVA (p < 0.001), UIVA (p < 0.001), VRQOL (p < 0.001), CS (p < 0.001), and CMT (p < 0.001) compared to baseline. Notably, the Eyhance ICB00 group showed a significantly higher UCIVA value at 6 months post-surgery when compared to the Tecnis ZCB00 group (p = 0.001), while other parameters did not show significant differences between the groups.

Conclusion: The Eyhance IOL significantly improved both intermediate and distance visual acuity, with no notable difference in quality of life or CS compared to the Tecnis ZCB00 IOL after IEM removal. It appears to be a favorable choice for combined cataract and vitreoretinal surgery, offering enhanced vision for daily tasks and a promising alternative to traditional monofocal IOLs.

导言:本研究的目的是评估特发性视网膜外膜(IEM)患者在接受虹膜玻璃体切除术后新生成的单焦点眼内人工晶体(IOL)的临床疗效和生活质量:在这项前瞻性研究中,42 名特发性视网膜外膜(IEM)和白内障患者接受了玻璃体旁切除术(PPV)。他们被分为 ICB00 组(21 名患者)和 ZCB00 组(21 名患者)。对两组患者手术前后收集的数据进行比较,包括未矫正远视力(UDVA)、未矫正中视力(UIVA)、视觉相关生活质量(VRQOL)、眼压(IOP)、对比敏感度(CS)和黄斑中心厚度(CMT):结果:两组患者的术前特征无明显差异。然而,在术后 6 个月的随访中,UDVA(p < 0.001)、UIVA(p < 0.001)、VRQOL(p < 0.001)、CS(p < 0.001)和 CMT(p < 0.001)与基线相比均有显著改善。值得注意的是,与 Tecnis ZCB00 组相比,Eyhance ICB00 组在术后 6 个月的 UCIVA 值明显更高(p=0.001),而其他参数在各组之间没有明显差异:结论:Eyhance人工晶体与Tecnis ZCB00人工晶体相比,在摘除IEM后,Eyhance人工晶体明显改善了中距离和远距离视力,在生活质量和对比敏感度方面没有明显差异。它似乎是白内障和玻璃体视网膜联合手术的有利选择,可提高日常工作的视力,是传统单焦点人工晶体的理想替代品。
{"title":"Clinical Outcomes of a New Monofocal Intraocular Lens in Patients Undergoing Phacovitrectomy for Idiopathic Epiretinal Membrane.","authors":"Tomislav Jukić, Gentian Bajraktari, Nenad Vukojević, Martin Oroz, Andrea Radolović, Krešimir Mandić, Miro Kalauz","doi":"10.1159/000540362","DOIUrl":"10.1159/000540362","url":null,"abstract":"<p><strong>Introduction: </strong>The purpose of this study was to evaluate the clinical outcomes and quality of life of newly generated monofocal intraocular lens (IOL) in patients diagnosed with idiopathic epiretinal membrane (IEM) following phacovitrectomy.</p><p><strong>Methods: </strong>In this prospective study, 42 patients with IEM and cataract underwent pars plana vitrectomy. They were divided into the ICB00 group (21 patients) and the ZCB00 group (21 patients). Data collected before and after the surgery were compared between the two groups, including uncorrected distance visual acuity (UDVA), uncorrected intermediate visual acuity (UIVA), vision-related quality of life (VRQOL), intraocular pressure, contrast sensitivity (CS), and central macular thickness (CMT).</p><p><strong>Results: </strong>The preoperative characteristics of the two groups showed no significant differences. However, at the 6-month follow-up after surgery, there were significant improvements in UDVA (p &lt; 0.001), UIVA (p &lt; 0.001), VRQOL (p &lt; 0.001), CS (p &lt; 0.001), and CMT (p &lt; 0.001) compared to baseline. Notably, the Eyhance ICB00 group showed a significantly higher UCIVA value at 6 months post-surgery when compared to the Tecnis ZCB00 group (p = 0.001), while other parameters did not show significant differences between the groups.</p><p><strong>Conclusion: </strong>The Eyhance IOL significantly improved both intermediate and distance visual acuity, with no notable difference in quality of life or CS compared to the Tecnis ZCB00 IOL after IEM removal. It appears to be a favorable choice for combined cataract and vitreoretinal surgery, offering enhanced vision for daily tasks and a promising alternative to traditional monofocal IOLs.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"251-260"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141856141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Approaches in the Management of Submacular Hemorrhages. 治疗眼底出血的新方法。
IF 2.1 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-01-01 Epub Date: 2024-09-13 DOI: 10.1159/000541451
Matias Iglicki, Dinah Zur
{"title":"New Approaches in the Management of Submacular Hemorrhages.","authors":"Matias Iglicki, Dinah Zur","doi":"10.1159/000541451","DOIUrl":"10.1159/000541451","url":null,"abstract":"","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"275-276"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142292798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis. 静脉内曲安奈德治疗糖尿病黄斑水肿和视网膜静脉闭塞继发黄斑水肿:一项荟萃分析。
IF 2.1 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-01-01 Epub Date: 2023-08-14 DOI: 10.1159/000533443
Andrew Mihalache, Amin Hatamnejad, Nikhil S Patil, Marko M Popovic, Peter J Kertes, Miguel Cruz-Pimentel, Rajeev H Muni

Background: The comparative safety and efficacy of different doses of intravitreal triamcinolone acetonide (IVTA) for diabetic macular edema (DME) and macular edema (ME) secondary to retinal vein occlusion (RVO) is unclear.

Objectives: This meta-analysis aimed to compare the safety and efficacy of different doses of IVTA in this setting.

Methods: A systematic literature search for randomized clinical trials (RCTs) was conducted on Cochrane Library, Ovid MEDLINE, and EMBASE from January 2005 to May 2022. Studies that reported on patients with DME or ME secondary to RVO that received treatment with different doses of IVTA were included. A random-effects meta-analysis was performed. Cochrane's Risk of Bias Tool 2 was used to assess the risk of bias, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) guidelines were used to assess certainty of evidence.

Results: Five RCTs reporting on 1,041 eyes at baseline were included in this meta-analysis. In eyes with ME secondary to RVO, high-dose (4 mg) IVTA achieved a significantly better change in best-corrected visual acuity (WMD = -4.75 ETDRS letters, 95% CI = [-7.73, -1.78], p = 0.002) and reduction in retinal thickness (WMD = -93.02 μm, 95% CI = [-153.23, -32.82], p = 0.002) at months 4-6 compared to low-dose (1-2 mg) IVTA. However, high-dose IVTA had a higher risk of intraocular pressure-related adverse events (RR = 2.99, 95% CI = [1.05, 8.50], p = 0.04) and cataract surgery (RR = 5.67, 95% CI = [3.09, 10.41], p < 0.00001) than low-dose IVTA in eyes with ME secondary to RVO. These efficacy and safety differences in high-dose and low-dose IVTA were not observed in DME eyes.

Conclusions: The RCT evidence in this setting is limited. High-dose IVTA achieved greater improvements in visual acuity and reductions in retinal thickness than low-dose IVTA at months 4-6. However, high-dose IVTA had a less favorable safety profile than low-dose IVTA. The significance of these outcomes was based on patients with ME secondary to RVO, but not DME.

背景:不同剂量的玻璃体内曲安奈德(IVTA)治疗糖尿病黄斑水肿(DME)和视网膜静脉闭塞(RVO)继发的黄斑水肿(ME)的安全性和有效性比较尚不清楚:这项荟萃分析旨在比较不同剂量的IVTA在这种情况下的安全性和有效性:方法:2005 年 1 月至 2022 年 5 月,在 Cochrane Library、Ovid MEDLINE 和 EMBASE 上对随机临床试验 (RCT) 进行了系统性文献检索。这些研究报告了继发于 RVO 的 DME 或 ME 患者接受不同剂量 IVTA 治疗的情况。进行了随机效应荟萃分析。采用Cochrane的偏倚风险工具2评估偏倚风险,并采用建议、评估、发展和评价分级(GRADE)指南评估证据的确定性:本次荟萃分析共纳入了五项RCT研究,报告了1,041只眼睛的基线数据。与低剂量(1-2 毫克)IVTA 相比,在继发于 RVO 的 ME 患者中,高剂量(4 毫克)IVTA 在第 4-6 个月的最佳矫正视力变化(WMD=-4.75 ETDRS 字母,95%CI=[-7.73,-1.78],p=.002)和视网膜厚度减少(WMD=-93.02 微米,95%CI=[-153.23,-32.82],p=.002)方面取得了显著改善。然而,高剂量IVTA发生眼压相关不良事件(RR=2.99,95%CI=[1.05,8.50],P=.04)和白内障手术(RR=5.67,95%CI=[3.09,10.41],P=.41)的风险更高:这种情况下的 RCT 证据有限。与低剂量IVTA相比,高剂量IVTA在第4-6个月的视力改善和视网膜厚度减少方面取得了更大的进步。但是,高剂量 IVTA 的安全性不如低剂量 IVTA。这些结果的意义基于继发于RVO的ME患者,而非DME患者。
{"title":"Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis.","authors":"Andrew Mihalache, Amin Hatamnejad, Nikhil S Patil, Marko M Popovic, Peter J Kertes, Miguel Cruz-Pimentel, Rajeev H Muni","doi":"10.1159/000533443","DOIUrl":"10.1159/000533443","url":null,"abstract":"<p><strong>Background: </strong>The comparative safety and efficacy of different doses of intravitreal triamcinolone acetonide (IVTA) for diabetic macular edema (DME) and macular edema (ME) secondary to retinal vein occlusion (RVO) is unclear.</p><p><strong>Objectives: </strong>This meta-analysis aimed to compare the safety and efficacy of different doses of IVTA in this setting.</p><p><strong>Methods: </strong>A systematic literature search for randomized clinical trials (RCTs) was conducted on Cochrane Library, Ovid MEDLINE, and EMBASE from January 2005 to May 2022. Studies that reported on patients with DME or ME secondary to RVO that received treatment with different doses of IVTA were included. A random-effects meta-analysis was performed. Cochrane's Risk of Bias Tool 2 was used to assess the risk of bias, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) guidelines were used to assess certainty of evidence.</p><p><strong>Results: </strong>Five RCTs reporting on 1,041 eyes at baseline were included in this meta-analysis. In eyes with ME secondary to RVO, high-dose (4 mg) IVTA achieved a significantly better change in best-corrected visual acuity (WMD = -4.75 ETDRS letters, 95% CI = [-7.73, -1.78], p = 0.002) and reduction in retinal thickness (WMD = -93.02 μm, 95% CI = [-153.23, -32.82], p = 0.002) at months 4-6 compared to low-dose (1-2 mg) IVTA. However, high-dose IVTA had a higher risk of intraocular pressure-related adverse events (RR = 2.99, 95% CI = [1.05, 8.50], p = 0.04) and cataract surgery (RR = 5.67, 95% CI = [3.09, 10.41], p &lt; 0.00001) than low-dose IVTA in eyes with ME secondary to RVO. These efficacy and safety differences in high-dose and low-dose IVTA were not observed in DME eyes.</p><p><strong>Conclusions: </strong>The RCT evidence in this setting is limited. High-dose IVTA achieved greater improvements in visual acuity and reductions in retinal thickness than low-dose IVTA at months 4-6. However, high-dose IVTA had a less favorable safety profile than low-dose IVTA. The significance of these outcomes was based on patients with ME secondary to RVO, but not DME.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"19-29"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10836924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10353149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Baseline Features in Polypoidal Choroidal Vasculopathy in Caucasian Patients. 白种人多发性脉络膜血管病的基线特征。
IF 2.1 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-01-01 Epub Date: 2024-10-02 DOI: 10.1159/000540911
Maria Ludovica Ruggeri, Lisa Toto, Rossella D'Aloisio, Anna Romano, Alberto Quarta, Matteo Gironi, Federico Formenti, Raffaella Aloia, Annamaria Porreca, Marta Di Nicola, Rodolfo Mastropasqua

Introduction: The aim of this study was to investigate demographic, anatomical, angiographic, and functional parameters in patients suffering from polypoidal choroidal vasculopathy (PCV).

Methods: Sixty eyes of 60 patients with a definite diagnosis of treatment-naïve exudative unilateral PCV were evaluated in this retrospective study. Fellow eyes and age-matched healthy subjects were enrolled as comparison. All subjects underwent complete ophthalmic evaluation with multimodal imaging assessment, including spectral-domain optical coherence tomography (OCT) and OCT angiography. Main outcome measures in the comparison analysis were central macular thickness (CMT), subfoveal choroidal thickness (SFCT), and choroidal vascularity index (CVI), whereas outcome measures for correlation analyses were best corrected visual acuity (BCVA), intraretinal fluid and subretinal fluid (SRF) presence, SRF thickness, vascularized pigmented epithelial detachment height, and PCV outer retina to choriocapillaris flow area.

Results: CVI was significantly higher in affected and fellow eyes if compared with the healthy ones (p = 0.049; p = 0.003). Subfoveal choroid resulted to be thicker in the diseased eyes when compared with healthy ones (p = 0.002). A negative correlation was assessed between age and SFCT, CMT, and BCVA. In addition, a significant association between male gender and anatomical and functional parameters has been found with male prevalence at baseline in cases. No association between systemic conditions and PCV features was found.

Conclusions: Patients with unilateral PCV show choroidal changes in terms of higher values of CVI, also in fellow eyes, that were negatively related with age. In our cohort of patients, males showed the poorest diagnosis with a baseline lower BCVA and higher CMT when compared with females. PCV was not associated with any systemic condition.

研究背景这项研究旨在调查多形性脉络膜血管病(PCV)患者的人口统计学、解剖学、血管造影和功能参数。方法:这项回顾性研究评估了60名确诊为未经治疗的渗出性单侧PCV患者的60只眼睛。同眼和年龄匹配的健康受试者作为对比。所有受试者均接受了全面的眼科评估和多模态成像评估,包括光谱域(SD)光学相干断层扫描(OCT)和 OCT 血管造影(OCTA)。对比分析的主要结果指标是黄斑中心厚度(CMT)、脉络膜下厚度(SFCT)和脉络膜血管指数(CVI),而相关分析的结果指标是最佳矫正视力(BCVA)、视网膜内积液(IRF)和视网膜下积液(SRF)、SRF 厚度(SRFT)、血管化色素上皮脱离(VPED)高度和 PCV 外视网膜至绒毛膜(ORCC)血流面积(ORCCFA)。结果与健康眼相比,患眼和同侧眼的 CVI 明显更高(P=0.049;P=0.003)。与健康眼相比,患病眼的眼底脉络膜更厚(p=0.002)。年龄与 SFCT、CMT 和 BCVA 之间呈负相关。此外,还发现男性性别与解剖和功能参数之间存在明显关联,病例中男性基线发病率较高。没有发现全身状况与 PCV 特征之间存在关联:结论:单眼 PCV 患者的脉络膜变化表现为较高的 CVI 值,同眼也是如此,且与年龄呈负相关。与女性患者相比,男性患者的诊断结果最差,BCVA基线值较低,CMT较高。PCV 与任何全身性疾病无关。
{"title":"Baseline Features in Polypoidal Choroidal Vasculopathy in Caucasian Patients.","authors":"Maria Ludovica Ruggeri, Lisa Toto, Rossella D'Aloisio, Anna Romano, Alberto Quarta, Matteo Gironi, Federico Formenti, Raffaella Aloia, Annamaria Porreca, Marta Di Nicola, Rodolfo Mastropasqua","doi":"10.1159/000540911","DOIUrl":"10.1159/000540911","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to investigate demographic, anatomical, angiographic, and functional parameters in patients suffering from polypoidal choroidal vasculopathy (PCV).</p><p><strong>Methods: </strong>Sixty eyes of 60 patients with a definite diagnosis of treatment-naïve exudative unilateral PCV were evaluated in this retrospective study. Fellow eyes and age-matched healthy subjects were enrolled as comparison. All subjects underwent complete ophthalmic evaluation with multimodal imaging assessment, including spectral-domain optical coherence tomography (OCT) and OCT angiography. Main outcome measures in the comparison analysis were central macular thickness (CMT), subfoveal choroidal thickness (SFCT), and choroidal vascularity index (CVI), whereas outcome measures for correlation analyses were best corrected visual acuity (BCVA), intraretinal fluid and subretinal fluid (SRF) presence, SRF thickness, vascularized pigmented epithelial detachment height, and PCV outer retina to choriocapillaris flow area.</p><p><strong>Results: </strong>CVI was significantly higher in affected and fellow eyes if compared with the healthy ones (p = 0.049; p = 0.003). Subfoveal choroid resulted to be thicker in the diseased eyes when compared with healthy ones (p = 0.002). A negative correlation was assessed between age and SFCT, CMT, and BCVA. In addition, a significant association between male gender and anatomical and functional parameters has been found with male prevalence at baseline in cases. No association between systemic conditions and PCV features was found.</p><p><strong>Conclusions: </strong>Patients with unilateral PCV show choroidal changes in terms of higher values of CVI, also in fellow eyes, that were negatively related with age. In our cohort of patients, males showed the poorest diagnosis with a baseline lower BCVA and higher CMT when compared with females. PCV was not associated with any systemic condition.</p>","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"322-330"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142366071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancing the Frontiers of Retinal Vasculitis: Insights, Challenges, and Future Directions. 推进视网膜血管炎的前沿研究:洞察力、挑战和未来方向。
IF 2.1 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-01-01 Epub Date: 2024-10-10 DOI: 10.1159/000541813
Marion R Munk, Emmett T Cunningham
{"title":"Advancing the Frontiers of Retinal Vasculitis: Insights, Challenges, and Future Directions.","authors":"Marion R Munk, Emmett T Cunningham","doi":"10.1159/000541813","DOIUrl":"10.1159/000541813","url":null,"abstract":"","PeriodicalId":19595,"journal":{"name":"Ophthalmologica","volume":" ","pages":"277-279"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Ophthalmologica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1